IL2RA and myeloid sarcoma: Along this line, increased local bioavailability of IL-2 by blocking the IL-2Rα chain (CD25) on recently activated T cells upon treatment with daclizumab is associated with expansion and activation of CD56bright NK cells in multiple sclerosis (MS) patients (19–21).